P
Paul R. Harnett
Researcher at Westmead Hospital
Publications - 115
Citations - 5805
Paul R. Harnett is an academic researcher from Westmead Hospital. The author has contributed to research in topics: Ovarian cancer & Serous fluid. The author has an hindex of 32, co-authored 104 publications receiving 4582 citations. Previous affiliations of Paul R. Harnett include Millennium Institute & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch,Ann-Marie Patch,Elizabeth L. Christie,Dariush Etemadmoghadam,Dariush Etemadmoghadam,Dale W. Garsed,Joshy George,Sian Fereday,Katia Nones,Katia Nones,Prue A. Cowin,Kathryn Alsop,Peter Bailey,Peter Bailey,Karin S. Kassahn,Karin S. Kassahn,Felicity Newell,Michael C.J. Quinn,Michael C.J. Quinn,Stephen H. Kazakoff,Stephen H. Kazakoff,Kelly Quek,Charlotte Wilhelm-Benartzi,Edward Curry,Huei San Leong,Anne Hamilton,Anne Hamilton,Anne Hamilton,Linda Mileshkin,George Au-Yeung,Catherine Kennedy,Jillian Hung,Yoke Eng Chiew,Paul R. Harnett,Michael Friedlander,Michael C. J. Quinn,Jan Pyman,Stephen Cordner,Patricia C. M. O’Brien,Jodie Leditschke,Greg Young,Kate Strachan,Paul Waring,Walid J Azar,Chris Mitchell,Nadia Traficante,Joy Hendley,Heather Thorne,Mark Shackleton,David Miller,Gisela Mir Arnau,Richard W. Tothill,Timothy P. Holloway,Timothy Semple,Ivon Harliwong,Craig Nourse,Ehsan Nourbakhsh,Suzanne Manning,Senel Idrisoglu,Timothy J. C. Bruxner,Angelika N. Christ,Barsha Poudel,Oliver Holmes,Oliver Holmes,Matthew J. Anderson,Conrad Leonard,Conrad Leonard,Andrew Lonie,Nathan E. Hall,Scott Wood,Scott Wood,Darrin Taylor,Qinying Xu,Qinying Xu,J. Lynn Fink,Nick Waddell,Ronny Drapkin,Euan A. Stronach,Hani Gabra,Robert S. Brown,A. Jewell,Shivashankar H. Nagaraj,Emma Markham,Peter Wilson,Jason Ellul,Orla McNally,Maria A. Doyle,Ravikiran Vedururu,Collin Stewart,Ernst Lengyel,John V. Pearson,John V. Pearson,Nicola Waddell,Nicola Waddell,Anna deFazio,Sean M. Grimmond,Sean M. Grimmond,David D.L. Bowtell,David D.L. Bowtell,David D.L. Bowtell +99 more
TL;DR: It is shown that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance.
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas
Dariush Etemadmoghadam,Anna deFazio,Rameen Beroukhim,Craig H. Mermel,Joshy George,Gad Getz,Richard W. Tothill,Aikou Okamoto,Maria B Raeder,Paul R. Harnett,Stephen Lade,Lars A. Akslen,Anna V. Tinker,Bianca Locandro,Kathryn Alsop,Yoke-Eng Chiew,Nadia Traficante,Sian Fereday,Daryl S Johnson,Stephen B. Fox,William R. Sellers,Mitsuyoshi Urashima,Helga B. Salvesen,Matthew Meyerson,David D.L. Bowtell +24 more
TL;DR: Two distinct mechanisms of primary treatment failure in serous ovarian cancer are identified, involving CCNE1 amplification and enhanced extracellular matrix deposition, andCCNE1 copy number is validated as a dominant marker of patient outcome in ovarian cancer.
Journal ArticleDOI
Dose-Response Association of CD8(+) Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Ellen L. Goode,Matthew S. Block,Kimberly R. Kalli,Robert A. Vierkant,Wenqian Chen,Zachary C. Fogarty,Aleksandra Gentry-Maharaj,A. Toloczko,Alexander Hein,Aliecia L. Bouligny,Aliecia L. Bouligny,Allan Jensen,Ana Osorio,Andreas D. Hartkopf,Andy Ryan,Anita Chudecka-Głaz,Anthony M. Magliocco,Arndt Hartmann,Audrey Y. Jung,Bo Gao,Brenda Y. Hernandez,Brooke L. Fridley,Bryan M. McCauley,Catherine J. Kennedy,Catherine J. Kennedy,Chen Wang,Chloe Karpinskyj,Christiani Bisinoto de Sousa,Daniel Guimarães Tiezzi,David L. Wachter,Esther Herpel,Florin Andrei Taran,Francesmary Modugno,Gregg Nelson,Jan Lubinski,Janusz Menkiszak,Jennifer Alsop,Jenny Lester,Jesús García-Donas,Jill Nation,Jillian Hung,Jillian Hung,José Palacios,Joseph H. Rothstein,Joseph L. Kelley,Jurandyr Moreira de Andrade,Luis Robles-Díaz,Maria P. Intermaggio,Martin Widschwendter,Matthias W. Beckmann,Matthias Ruebner,Mercedes Jimenez-Linan,Naveena Singh,Oleg Oszurek,Paul R. Harnett,Peter F Rambau,Peter F Rambau,Peter Sinn,Philipp Wagner,Prafull Ghatage,Raghwa Sharma,Raghwa Sharma,Robert P. Edwards,Roberta B. Ness,Sandra Orsulic,Sara Y. Brucker,Sharon E. Johnatty,Teri A. Longacre,Ursula Eilber,Valerie McGuire,Weiva Sieh,Yanina Natanzon,Zheng Li,Zheng Li,Alice S. Whittemore,Anna deFazio,Anna deFazio,Annette Staebler,Beth Y. Karlan,Blake Gilks,David D.L. Bowtell,David D.L. Bowtell,David D.L. Bowtell,Estrid Høgdall,Francisco José Candido dos Reis,Helen Steed,Ian G. Campbell,Ian G. Campbell,Jacek Gronwald,Javier Benitez,Jennifer M Koziak,Jenny Chang-Claude,Jenny Chang-Claude,Kirsten B. Moysich,Linda E. Kelemen,Linda S. Cook,Marc T. Goodman,Maria J. Garcia,Peter A. Fasching,Peter A. Fasching,Stefan Kommoss,Suha Deen,Susanne K. Kjaer,Usha Menon,James D. Brenton,Paul D.P. Pharoah,Georgia Chenevix-Trench,David G. Huntsman,David G. Huntsman,Stacey J. Winham,Martin Köbel,Susan J. Ramus,Susan J. Ramus +112 more
TL;DR: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival and suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.
Journal ArticleDOI
ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer
Ellen L. Hedditch,Bo Gao,Amanda J. Russell,Yi Lu,Catherine Emmanuel,Jonathan Beesley,Sharon E. Johnatty,Xiaoqing Chen,Paul R. Harnett,Joshy George,Rebekka T. Williams,Claudia Flemming,Diether Lambrechts,Evelyn Despierre,Sandrina Lambrechts,Ignace Vergote,Beth Y. Karlan,Jenny Lester,Sandra Orsulic,Christine Walsh,Peter A. Fasching,Peter A. Fasching,Matthias W. Beckmann,Arif B. Ekici,Alexander Hein,Keitaro Matsuo,Satoyo Hosono,Toru Nakanishi,Yasushi Yatabe,Tanja Pejovic,Yukie Bean,Florian Heitz,Florian Heitz,Philipp Harter,Andreas du Bois,Ira Schwaab,Estrid Høgdall,S.K. Kjaer,Allan Jensen,Claus Høgdall,Lene Lundvall,Svend Aage Engelholm,Bob Brown,James M. Flanagan,Michelle D Metcalf,Nadeem Siddiqui,Thomas A. Sellers,Brooke L. Fridley,Julie M. Cunningham,Joellen M. Schildkraut,Ed Iversen,Rachel Palmieri Weber,Andrew Berchuck,Ellen L. Goode,David D.L. Bowtell,Georgia Chenevix-Trench,Anna deFazio,Murray D. Norris,Stuart MacGregor,Michelle Haber,Michelle J. Henderson +60 more
TL;DR: In this article, the relationship between clinical outcomes and ABC transporter gene expression in two independent cohorts of high-grade serous EOC tumors was assessed with real-time quantitative polymerase chain reaction, analysis of expression microarray data, and immunohistochemistry.